Envestnet Portfolio Solutions Inc. decreased its position in shares of DaVita Inc. (NYSE:DVA - Free Report) by 31.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 18,269 shares of the company's stock after selling 8,519 shares during the period. Envestnet Portfolio Solutions Inc.'s holdings in DaVita were worth $2,732,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors have also made changes to their positions in DVA. Atria Investments Inc boosted its position in shares of DaVita by 12.3% during the 3rd quarter. Atria Investments Inc now owns 2,897 shares of the company's stock worth $475,000 after acquiring an additional 317 shares in the last quarter. Empowered Funds LLC boosted its position in shares of DaVita by 25.6% during the 3rd quarter. Empowered Funds LLC now owns 5,824 shares of the company's stock worth $955,000 after acquiring an additional 1,187 shares in the last quarter. Thrivent Financial for Lutherans lifted its stake in DaVita by 49.4% in the 3rd quarter. Thrivent Financial for Lutherans now owns 8,131 shares of the company's stock valued at $1,333,000 after purchasing an additional 2,688 shares during the last quarter. Quest Partners LLC bought a new position in DaVita in the 3rd quarter valued at approximately $669,000. Finally, B. Metzler seel. Sohn & Co. Holding AG bought a new position in DaVita in the 3rd quarter valued at approximately $923,000. Institutional investors and hedge funds own 90.12% of the company's stock.
Analyst Upgrades and Downgrades
Several equities analysts recently commented on DVA shares. Sanford C. Bernstein set a $184.00 price objective on shares of DaVita in a research note on Friday, February 21st. StockNews.com downgraded shares of DaVita from a "buy" rating to a "hold" rating in a research note on Friday. Cowen reissued a "hold" rating on shares of DaVita in a research note on Tuesday, February 18th. Finally, Barclays increased their price objective on shares of DaVita from $164.00 to $169.00 and gave the company an "equal weight" rating in a research note on Tuesday, February 18th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and one has given a buy rating to the company. Based on data from MarketBeat.com, DaVita has a consensus rating of "Hold" and an average target price of $166.33.
Check Out Our Latest Analysis on DVA
DaVita Trading Down 0.5 %
Shares of DVA stock traded down $0.76 during trading hours on Friday, hitting $148.25. 1,036,193 shares of the company's stock traded hands, compared to its average volume of 784,179. The stock's 50 day simple moving average is $158.53 and its 200 day simple moving average is $157.51. The stock has a market cap of $11.86 billion, a PE ratio of 13.80, a price-to-earnings-growth ratio of 1.07 and a beta of 0.99. DaVita Inc. has a 12 month low of $125.64 and a 12 month high of $179.60. The company has a quick ratio of 1.21, a current ratio of 1.26 and a debt-to-equity ratio of 23.18.
DaVita (NYSE:DVA - Get Free Report) last released its quarterly earnings results on Thursday, February 13th. The company reported $2.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. On average, sell-side analysts anticipate that DaVita Inc. will post 10.76 EPS for the current year.
DaVita Profile
(
Free Report)
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Further Reading
Before you consider DaVita, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DaVita wasn't on the list.
While DaVita currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
